Is GTBP up or down today?
GTBP is up 39.32% today, last at 8.61. This stock moved +39.32% versus the prior close.
GTBP · GTBP
GTBP (GTBP) is trading at 8.61, up 39.32% on the session. GTBP sits at the 13% mark of its 52-week range, carries a 14-day RSI of 99, and trades above its 50-day average. Over the past month it is up 2650.80%.
Leading the coverage: “GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum Builds - Ichimoku TK Cross - dars.gov.et” (Google News Company, 10d ago). GTBP is +2942.40% since story.
GTBP trades on a trailing P/E of 8.6 and is running 2651.86% ahead of the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
GTBP is up 39.32% today, last at 8.61. This stock moved +39.32% versus the prior close.
Leading the coverage: “GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum Builds - Ichimoku TK Cross - dars.gov.et” (Google News Company, 10d ago). GTBP is +2942.40% since story. Dominant story: Why Has GT Biopharma (GTBP) Become a Talking Point? - Kalkine Media (1 source, neutral) RSI is 99 — overbought (heated) Price above 50-day average — short-term uptrend Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (123 days) · Drag or scroll left for earlier dates
Why Has GT Biopharma (GTBP) Become a Talking Point? - Kalkine Media
GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript
EBITDA per share of GT Biopharma Inc – MUN:OXI - TradingView
GT Biopharma Pops Ahead of Presentation - Baystreet.ca
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026 - marketscreener.com